While younger mRUNX1 patients treated with intensive chemotherapy and a subgroup of older mRUNX1 patients with prior MDS/MPN exhibited inferior treatment responses, the majority of mRUNX1 AML patients included older patients treated with HMA therapy, in whom treatment responses and clinical outcomes were not inferior compared to RUNX1 wild-type. This evidence concerns the gene RUNX1 and acute myeloid leukemia.